Marisa Wexler, MS, senior science writer —

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

Threat of Antibiotic Resistance a Shot in the Arm for Phage Research

Yale University last month launched the Center for Phage Biology and Therapy, a new endeavor to advance research into using viruses to address the growing concern about antibiotic-resistant bacteria. Since the first antibiotics were discovered nearly a century ago, bacteria-killing medicines have revolutionized humanity’s ability to combat bacterial infections. However,…

New Capsule Form of Adrulipase Alfa for EPI May Soon Enter Trial

First Wave BioPharma has filed two new patents related to adrulipase, a yeast-derived enzyme that the company is developing to treat exocrine pancreatic insufficiency in people with cystic fibrosis (CF). One application is related to dosage forms, methods of treatment, and manufacturing methods for the investigational medication. This includes a…

CF Foundation Awards $3.5M to Develop Antibiotic ACG-701

The Cystic Fibrosis Foundation has awarded up to $3.5 million to Aceragen to support the clinical development of ACG-701, an investigational antibiotic to treat pulmonary exacerbations in people with cystic fibrosis (CF). “We appreciate the generous support of the Cystic Fibrosis Foundation and are looking forward to…

Kaftrio Approved for Children Ages 6 and Up in European Union, UK

The European Commission has expanded its approval of Kaftrio (ivacaftor/tezacaftor/elexacaftor), in combination with Kalydeco (ivacaftor), to treat children with cystic fibrosis (CF) as young as 6 who have the most common type of CF-causing mutation. The Medicines and Healthcare Products Regulatory Agency (MHRA) in the U.K. approved a similar expansion.

CF Foundation Invests in SalioGen’s Gene Coding Therapy

The Cystic Fibrosis Foundation has announced an investment in SalioGen Therapeutics to support the company’s preclinical research toward  developing a new gene therapy for cystic fibrosis (CF). SalioGen is working to advance a novel type of gene therapy, called Gene Coding, which is accomplished using the company’s…